AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG

Eli Lilly

Pfizer

Sanofi

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

SPDR S&P 500 ETF Trust

WestRock

George Soros is among the most renowned and controversial hedge fund managers on the planet.

Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.

AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor

AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially.  The FTSE 100 group struck an exclusive license deal for a pre-clinical novel molecule that has shown it can prevent the formation of types of particles that carry cholesterol in the bloodstream, known as lipoproteins, which are a combination of fat and protein.

AstraZeneca buys licence for cholesterol treatment from China's CSPC

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca's AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.1 The trial included patients with intermittent or mild persistent asthma, including those on short-acting.

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.

AstraZeneca to pay up to $2 billion to license cardiovascular drug

AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.

AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC

London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has delivered positive results. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction1 in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.

Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patients

The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.

AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing.

CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma

Arcus Biosciences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients wi.

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin's ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a Fre.

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.

AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.

AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?

The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.

AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC

Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.

Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.

AstraZeneca in AI collaboration with Immunai to inform cancer drug trials

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.

AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AstraZeneca PLC (NASDAQ:AZN ) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Conference Call Participants Zafar Aziz - Deutsche Bank Hello and welcome to the Deutsche Bank Depositary Receipts of Virtual Investor Conference. My name is Zafar Aziz from the Deutsche Bank team.

AstraZeneca PLC (AZN) Annual Deutsche Bank Leveraged Finance Conference (Transcript)

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.

CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease

AstraZeneca possesses all the key qualities of a qualitative dividend stock. The company topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. AstraZeneca boasts a balance sheet that's A-rated by S&P.

AstraZeneca: Buy This Big Pharma Stock At A Discount Now

British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "statistical significance" in improving the length of time patients with certain types of breast cancer lived.

AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug

AstraZeneca PLC (LSE:AZN) shares fell to a five-month low after it confirmed that another failed cancer trial of its Dato-DXd drug. The largest company in the FTSE 100 said it will continue to talk to regulators despite Phase III trial results of datopotamab deruxtecan (Dato-DXd) on patients with late-stage breast cancer showed it “did not achieve statistical significance”, ie help survival rates, compared to typical chemotherapy treatment.

News for AstraZeneca Stock (AZN)